ReviewHuman vaccines & immunotherapeutics2017
Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era.
Review in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- An Age-stratified, Randomized Immunogenicity Trial of Killed Oral Cholera Vaccine with Delayed Second Dose in Cameroon.The American journal of tropical medicine and hygiene · 2022Trial
- In-silico identification of anti-cholera phytochemicals from Indian medicinal plants.PloS one · 2026Article
- Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns.Nature medicine · 2025Article
- Modeling the impact of vaccine campaigns on the epidemic transmission dynamics of chikungunya virus outbreaks.Nature medicine · 2025Article
- Exploiting bacterial-origin immunostimulants for improved vaccination and immunotherapy: current insights and future directions.Cell & bioscience · 2024Review
- Article
- Immunogenicity and waning immunity from the oral cholera vaccine (Shanchol™) in adults residing in Lukanga Swamps of Zambia.PloS one · 2022Article
- Sachet water consumption as a risk factor for cholera in urban settings: Findings from a case control study in Kinshasa, Democratic Republic of the Congo during the 2017-2018 outbreak.PLoS neglected tropical diseases · 2021Article
- Cost-effectiveness of a reactive oral cholera immunization campaign using Shanchol™ in Malawi.Cost effectiveness and resource allocation : C/E · 2021Article
- Licensed and Recommended Inactivated Oral CholeraVaccines: From Development to Innovative Deployment.Tropical medicine and infectious disease · 2021Review
- Global oral cholera vaccine use, 2013-2018.Vaccine · 2020Review
- Whole genome sequence of Vibrio cholerae directly from dried spotted filter paper.PLoS neglected tropical diseases · 2019Article
- Strategy for a globally coordinated response to a priority neglected tropical disease: Snakebite envenoming.PLoS neglected tropical diseases · 2019Article
- Oral cholera vaccines and their impact on the global burden of disease.Human vaccines & immunotherapeutics · 2019Review
- Organization and implementation of an oral cholera vaccination campaign in an endemic urban setting in Dhaka, Bangladesh.Global health action · 2019Article
- The cholera outbreak in Yemen: lessons learned and way forward.BMC public health · 2018Review
- Cholera.Current epidemiology reports · 2018Article
- Oral Vaccine Delivery for Intestinal Immunity-Biological Basis, Barriers, Delivery System, and M Cell Targeting.Polymers · 2018Review
- Oral cholera vaccine coverage during a preventive door-to-door mass vaccination campaign in Nampula, Mozambique.PloS one · 2018Article
- Delivery cost analysis of a reactive mass cholera vaccination campaign: a case study of Shanchol™ vaccine use in Lake Chilwa, Malawi.BMC infectious diseases · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cholera remains an important but neglected public health threat, affecting the health of the poorest populations and imposing substantial costs on public health systems. Cholera can be eliminated where access to clean water, sanitation, and satisfactory hygiene practices are sustained, but major improvements in infrastructure continue to be a distant goal. New developments and trends of cholera disease burden, the creation of affordable oral cholera vaccines (OCVs) for use in developing countries, as well as recent evidence of vaccination impact has created an increased demand for cholera vaccines. The global OCV stockpile was established in 2013 and with support from Gavi, has assisted in achieving rapid access to vaccine in emergencies. Recent WHO prequalification of a second affordable OCV supports the stockpile goals of increased availability and distribution to affected populations. It serves as an essential step toward an integrated cholera control and prevention strategy in emergency and endemic settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.